Skip to Main Content
Contribute Try STAT+ Today

Sarepta Therapeutics on Thursday announced mixed results from the first randomized clinical trial of its gene therapy for Duchenne muscular dystrophy, raising questions about the path forward for the one-time, potentially curative treatment.

A single infusion of the treatment, called SRP-9001, produced large increases in a crucial muscle protein typically missing in children born with Duchenne. But the increases failed to coincide with statistically significant improvements in muscle function for all patients after one year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Sarepta CEO Doug Ingram; “The efficacy of SRP-9001 is not an issue”

    To quote “The Who”…. Meet the new boss, same as the old boss.

    The current and former CEO of Serepta have been gaslighting the Duchenne community for years.

    And when are they going to complete that confirmatory study of Eteplirsen?

Comments are closed.